Selective inhibition of PI3K110α as a novel therapeutic strategy for cetuximab‑resistant oral squamous cell carcinoma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Selective inhibition of PI3K110α as a novel therapeutic strategy for cetuximab‑resistant oral squamous cell carcinoma

Published:2020-07-07 Issue:3 Volume:44 Page:863-872
ISSN:1021-335X
Container-title:Oncology Reports
language:
Short-container-title:Oncol Rep

Author:

Tsuchihashi Hiroki¹,Naruse Tomofumi¹,Yanamoto Souichi¹,Okuyama Kohei¹,Furukawa Kohei¹,Omori Keisuke¹,Umeda Masahiro¹

Affiliation:

1. Department of Clinical Oral Oncology, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki 852‑8588, Japan

Publisher

Spandidos Publications

Subject

Cancer Research,Oncology,General Medicine

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The efficacy and potential mechanisms of pyrotinib in targeting EGFR and HER2 in advanced oral squamous cell carcinoma;BMC Oral Health;2024-08-06

2. Pharmacological PI3K inhibition in head and neck squamous cell carcinoma: A systematic review;Toxicology in Vitro;2023-04

3. Targeted therapy for head and neck cancer: signaling pathways and clinical studies;Signal Transduction and Targeted Therapy;2023-01-16

4. Complete response of recurrent oral squamous cell carcinoma treated with cetuximab in combination with radiotherapy: A case series;Oncology Letters;2022-10-19

5. The expression and prognostic significance of PIK3CB in lung adenocarcinoma;Annals of Diagnostic Pathology;2022-10

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP